Get the Stockscreener App
821.86
0.27%
-2.20
Pre-market:
820.52
-1.34
-0.16%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $821.86, with a volume of 2.93M.
It is down -0.27% in the last 24 hours and down -5.85% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$824.06
Open:
$814.95
24h Volume:
2.93M
Relative Volume:
0.88
Market Cap:
$781.10B
Revenue:
$45.04B
Net Income/Loss:
$10.59B
P/E Ratio:
70.18
EPS:
11.71
Net Cash Flow:
$414.30M
1W Performance:
-11.60%
1M Performance:
-5.85%
6M Performance:
-12.10%
1Y Performance:
+8.86%
1-Day Range:
$813.26
$834.65
1-Week Range:
$811.64
$931.38
52-Week Range:
$711.40
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
821.86 | 781.10B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
212.06 | 374.36B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.85 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
74.79 | 332.00B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
93.35 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
ProQR Announces Year End 2024 Operating and Financial Results - GlobeNewswire Inc.
Eli Lilly’s Promising Position in Weight Management Market Drives Buy Rating - TipRanks
Lilly, J&J boosted spending on executive security after UnitedHealth shooting - Reuters.com
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey
Telehealth platforms in senators’ crosshairs over relationship with Eli Lilly, Pfizer - STAT
Durbin, Warren, Welch, Sanders Demand Answers From Telehealth Companies Regarding Their Financial Relationship With Pfizer, Eli Lilly Amid Concerns - RiverBender.com
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly - Investopedia
Lilly CEO got a big payday (and an Olympics treat) - STAT
Eli Lilly Suit Over Compound Drugs Survives Dismissal - Law360
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes - STAT
Is Eli Lilly and Company (LLY) the Best Low Risk Stock to Buy In 2025? - Insider Monkey
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss - AOL
Unpacking the Latest Options Trading Trends in Eli Lilly - Benzinga
Eli Lilly & Co: Promising CagriSema Performance Justifies Buy Rating Despite Tolerability Concerns - TipRanks
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock? - Yahoo Finance
Is Eli Lilly Stock a Buy? - The Motley Fool
Why Eli Lilly Stock Flopped Today - The Motley Fool
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand. - Investor's Business Daily
Judge Denies Injunction for Copycats of Lilly's Weight Loss Drug - Bloomberg Law
Eli Lilly plans to launch weight-loss drug in emerging markets this year - Reuters.com
Eli Lilly to debut weight loss drug in China, India - baha news
Morgan Stanley maintains Eli Lilly Overweight rating, $1,146 target By Investing.com - Investing.com South Africa
Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says - Bilyonaryo Business News
Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says - Marketscreener.com
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus.com
Eli Lilly's Baricitinib Shows Promising Results for Adolescents with Severe Alopecia Areata - GuruFocus.com
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study - Investors | Eli Lilly and Company
Eli Lilly and Company (LLY): Jim Cramer Says ‘Don’t Sell’ – A Visionary Stock to Hold! - Insider Monkey
FDA Can Take Eli Lilly Weight Loss Drug Off Shortage List - Law360
Eli Lilly and Company (LLY): Among The Stocks With At Least $10 Million In Insider Sales Recently - Insider Monkey
Eli Lilly Says CEO David Ricks' 2024 Total Compensation Was $29.2 Million -March 07, 2025 at 04:10 pm EST - Marketscreener.com
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative - Indianapolis Business Journal
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugsWTAJ - WTAJ - www.wtaj.com
US judge denies injunction, restricting copies of Lilly weight-loss drug - Reuters
Eli Lilly and Company (LLY): Jim Cramer Sees a ‘Big Moat’ with Weight Loss Drug - Insider Monkey
Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients - Benzinga
Eli Lilly posts long-term data for eczema therapy Ebglyss - Seeking Alpha
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan - Benzinga
Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis - Investors | Eli Lilly and Company
Consumers can buy Zepbound and Wegovy direct from drugmakers if they pay cash - WBEZ Chicago
Big Money Returning for Eli Lilly - FX Empire
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding - Benzinga
Two telehealth firms turn to branded Zepbound as restrictions loom on copies - Reuters
Third Time Lucky? Eli Lilly and Eisai Get Another Shot At English Funding For Alzheimer’s Drugs - Citeline News & Insights
Teladoc, LifeMD partner with Eli Lilly on GLP-1s - Modern Healthcare
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss - Benzinga
In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai - FiercePharma
Petri Dish: Biotech leaves Worcester; Novo Nordisk, Eli Lilly partnerships - The Business Journals
US judge denies injunction on Eli Lilly’s weight-loss drug copies - Investing.com
Here’s Why Eli Lilly and Company (LLY) has Come Under Pressure - Yahoo Finance
Hims & Hers down as judge denies motion over end to Lilly’s Zepbound shortage - Seeking Alpha
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):